GB004 exhibits protective effects directly on epithelial cells using ex vivo organoid and monolayer cultures

GB004 exhibits protective effects directly on epithelial cells using ex vivo organoid and monolayer cultures

Now Enrolling: The PROSERA Phase 3 study of seralutinib in adults with Pulmonary Arterial Hypertension (PAH).

PROSERA clinical trial: NCT05934526

Learn more about the study